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Analysis of viral replication and pathogenicity after in vivo selection of human immunodeficiency virus type
1 (HIV-1) attenuated in vitro will help to define the functions involved in replication and pathogenesis in vivo.
Using the SCID-hu Thy/Liv mouse and human fetal thymus organ culture as in vivo models, we previously
defined HIV-1 env determinants (HXB2/LW) which were reverted for replication in vivo (L. Su et al., Virology
227:46–52, 1997). In this study, we examined the replication of four highly related HIV-1 clones directly derived
from Lai/IIIB or after selection in vivo to investigate the envelope gp120 determinants associated with
replication in macrophages and in the thymus models in vivo. The LW/C clone derived from the IIIB-infected
laboratory worker and HXB2/LW both efficiently infected monocyte-derived macrophages (MDM) and the
human thymus. Although the laboratory worker (LW) isolates showed altered tropism from IIIB, they still
predominantly used CXCR4 as coreceptors for infecting peripheral blood mononuclear cells, macrophages,
and the thymus. Interestingly, a single amino acid mutation in the V3 loop associated with resistance to
neutralizing antibodies was also essential for the replication activity of the LW virus in the thymus models but
not for its activity in infecting MDM. The LW virions were equally sensitive to a CXCR4 antagonist. We further
demonstrated that the LW HIV-1 isolate selected in vivo produced more infectious viral particles that
contained higher levels of the Env protein gp120. Thus, selection of the laboratory-attenuated Lai/IIIB isolate
in vivo leads to altered tropism but not coreceptor usage of the virus. The acquired replication activity in vivo
is correlated with an early A-to-T mutation in the V3 loop and increased virion association of HIV-1 Env gp120,
but it is genetically separable from the acquired replication activity in macrophages.
Human immunodeficiency virus type 1 (HIV-1) diseases
(AIDS) are associated with high levels of HIV-1 replication
and loss of CD41 T lymphocytes. HIV-1 can infect diverse cell
types, including CD41 T cells, macrophages, dendritic cells,
Langerhans cells, and hematopoietic progenitor cells (14, 26,
30, 39). However, the HIV-1 isolates employed in many studies
have been expanded and maintained in immortalized human
T-cell lines or phytohemagglutinin (PHA)-activated peripheral
blood mononuclear cells (PBMCs) in vitro. The different se-
lective pressures in vitro may have led to the generation of
HIV-1 variants with attenuated replication and pathogenicity
in vivo. Many laboratory-adapted isolates of HIV-1 accumulate
mutations in gene functions such as env, vpr, vpu, and nef (37).
A good example of such adaptation in vitro is Lai/IIIB (HTLV-
IIIB [9]). Initially derived from a patient blood sample and
cultured in MT2/B cells, Lai/IIIB stock was prepared by infect-
ing the human T-leukemia cell line, H9, with infected M2T/B
cell supernatant. Subsequent analyses of the genome from the
Lai/IIIB isolate showed that multiple changes accumulated
during expansion in vitro (37). For example, the HXB2 ge-
nome cloned from Lai/IIIB carries mutations that lead to pre-
mature termination of three of the nine open reading frames
(ORFs): vpr, vpu, and nef. Many other subtle mutations may
have also accumulated. These mutations do not usually af-
fect HIV-1 replication in vitro under specific culture condi-
tions, though some of them may enhance viral replication in
certain cell lines. It was recently reported that laboratory-
adapted HIV-1 isolates have accumulated mutations that
contribute to attenuated HIV replication and pathogenesis
in vivo (12).
Comparison of HIV-1 isolates attenuated in vitro with
pathogenic revertants selected in vivo will help to identify
important viral determinants for replication and pathogenesis
in vivo. One successful example is found in the simian-human
immunodeficiency virus (SHIV) env chimeric genome adapted
in monkeys. SHIV variants with enhanced replication and
pathogenicity have been isolated from monkeys infected with
SHIV recombinant viruses (19). Mutations in the HIV env
genes have been identified which contribute to enhanced rep-
lication in monkeys. Interestingly, env determinants have also
been defined that specifically contribute to CD4 T-cell deple-
tion (i.e., pathogenicity), but not replication, in monkeys (13).
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Therefore, unique env determinants have intrinsic replication
or pathogenic activity in monkeys.
The Lai/IIIB isolate and its infectious molecular clones (e.g.,
HXB2) infect T-cell lines such as H9 as well as PBMCs in vitro
but are replication defective in vivo (15, 35, 40). When a lab-
oratory worker was accidentally infected by Lai/IIIB, infectious
virus was isolated from plasma by infection of primary PBMCs
with macrophage tropism but not by infection of T-cell lines
(21, 44). We have previously employed the SCID-hu Thy/Liv
mouse as an in vivo model (29, 31) to study the replication of
HXB2 and of HXB2-recombinant viruses containing HIV-1
fragments isolated from the infected laboratory worker (40).
Like Lai/IIIB, HXB2 failed to replicate in the Thy/Liv organ or
in the human fetal thymus organ culture (HF-TOC) models (8,
40). Replacement of an HXB2 subgenomic fragment carrying
the env ORF with the corresponding fragment from the labo-
ratory worker (LW) isolate (LW12.3) generated a recombinant
virus (HXB2/LW) which replicated in SCID-hu Thy/Liv mice
and in the HF-TOC model (22, 40). The specific in vivo rep-
lication determinants were mapped to the V1-V3 region of the
HXB2/LW env gene (40). Therefore, the attenuated Lai/IIIB
isolate acquired in vivo replication activity by mutational re-
version of the env gene in the infected laboratory worker. In
addition, multiple mutations in the env and nef genes that lead
to reduced pathogenicity have been implicated (12).
We further showed here that the infectious LW/C clone
derived from the IIIB-infected laboratory worker (28), like
HXB2/LW, replicated to high levels in the SCID-hu Thy/Liv
mouse and HF-TOC models. As expected, both LW/C and
HXB2/LW efficiently infected monocyte-derived macrophages
(MDM). Although the LW isolates showed altered tropism
from IIIB, they still only used CXCR4 as coreceptors for in-
fecting PBMCs, macrophages, and the thymus. Interestingly, a
single amino acid mutation in the V3 loop associated with
resistance to neutralizing antibodies was also essential for the
replication activity of the LW/C clone in the thymus models.
The single mutation back to IIIB (LW/CIIIB) did not affect its
activity to infect MDM but impaired its replication in the
thymus. We further demonstrated that the LW HIV-1 isolate
selected in vivo produced more infectious viral particles that
contained higher levels of the Env gp120 protein. Thus, selec-
tion of the laboratory-attenuated Lai/IIIB isolate in vivo leads
to altered tropism but not coreceptor usage of the virus. The
acquired replication activity in vivo is correlated with increased
virion association of HIV-1 Env gp120 but not with the repli-
cation activity in MDM.
MATERIALS AND METHODS
HIV-1 replication in PBMCs and viral supernatant production. Equal
amounts of proviral DNA were transfected into 293T cells and supernatant was
used to infect PHA-activated PBMCs as described previously (22, 39). Superna-
tant was collected and the titer was determined by using a multinuclear activation
of galactosidase inhibitor (MAGI) assay, performed as previously described
using U-373-MAGI-CXCR4CEM glioblastoma cells (42). The supernatants with
titers greater than 5 3 104 infectious units (IU)/ml were stored as viral stock for
infection. HXB2 and HXB2/LW have been described previously (40). LW/C and
LW/CIIIB have also been reported elsewhere (28).
HIV-1 replication in MDM. MDM were isolated from peripheral blood of
HIV-seronegative donors as previously described (34). Approximately 5 3 105
monocytes were allowed to differentiate for 7 days in culture medium (RPMI
with 5% donor serum, 50 mg of streptomycin/ml, 50 U of penicillin G [Gibco
BRL]/ml), in 6-well tissue culture plates. The monolayers were then infected for
1 h at 37°C with 500 ml of virus stock ('5 3 104 IU/ml) or medium from
mock-infected PBMCs, washed three times with phosphate-buffered saline
(PBS), and then cultured for an additional 15 days. Virus replication was de-
tected by reverse transcriptase (RT) assays of culture medium aliquots removed
every 3 days prior to changing the medium.
HIV-1 Env-mediated cell fusion with MDM and U87 cells. Env-mediated
fusion was tested in a cell-cell fusion assay employing primary macrophage
targets as described previously (16). Effector 293T cells were infected with
recombinant vaccinia virus vP11T7 gene1, which expresses the T7 polymerase,
and then cotransfected with plasmids carrying env under control of the T7
promoter and a luciferase reporter gene under control of the SP6 promoter.
One-week-old MDM cultures were infected with recombinant vaccinia virus
vSIMBE/L, which expresses the SP6 RNA polymerase under control of a syn-
thetic vaccinia virus early-late promoter. After incubation overnight at 32°C in
the presence of rifampin (100 mg/ml), Env-expressing 293T cells were mixed with
macrophages and incubated for 6 h in the presence of rifampin and AraC (0.1
mM). Cells were lysed 6 h later for measurement of luciferase expression, which
results from fusion, content mixing, and SP6 polymerase transactivation of the
luciferase reporter gene. In parallel, U87 cells stably expressing CD4 alone or in
conjunction with CCR5 or CXCR4 (provided by D. Littman through the Na-
tional Institutes of Health [NIH] AIDS Reagent Program [6]) were used as
targets for fusion under identical conditions. Env from X4 strain UG024, which
utilizes CXCR4 only for entry into macrophages (45), was analyzed as a control.
Infection of SCID-hu Thy/Liv mice or HF-TOC. Animal transplantation pro-
cedures for SCID-hu Thy/Liv construction have been described previously (33).
Infection of SCID-Thy/Liv mice was performed as previously described (39).
Briefly, SCID-hu Thy/Liv mice were infected with supernatant collected from
PHA-activated PBMCs containing no HIV-1 (mock) or 4 3 104 IU of HIV-1/ml.
Fifty microliters ('2000 IU) was injected into each thymus graft. Biopsies were
removed from Thy/Liv organs at indicated times and thymocytes were analyzed
for p24 levels and proviral DNA.
The TOC procedures were modified from those described previously (8).
Briefly, human fetal thymuses (19 to 24 gestational weeks) were dissected into
'2-mm3 fragments containing at least 3 to 5 intact thymic lobules under a
dissecting microscope. These fragments were transferred onto sterile organ cul-
ture membranes (Millipore) floating on media (RPMI with 10% fetal calf serum,
50 mg of streptomycin/ml, 50 U of penicillin G/ml, 13 MEM vitamin solution
[Gibco/BRL], 13 insulin-transferrin-sodium selenite medium supplement [Sig-
ma]), in 6-well tissue culture plates. An equal amount of virus ('800 IU) in 20
ml of supernatant from infected PHA-stimulated PBMCs or control supernatant
from mock-infected PHA-stimulated human PBMCs was added to each frag-
ment. The fragments were then cultured at 37°C in 5% CO2 for 10 to 12 days with
daily changes of culture media. Thymocytes were teased out of the fragments and
analyzed as described above.
Viral replication assays. Measurement of p24 production (picograms per 106
thymocytes) was performed using a Vironostica p24 enzyme-linked immunosor-
bent assay (ELISA) kit (Organon Teknika Corp., Durham, N.C.) with cell lysates
in PBS–1% Triton X-100. RT assays to measure virus replication were per-
formed.
Flow cytometric analyses. Thymocytes isolated from SCID-hu Thy/Liv organs
or HF-TOC fragments were stained with PE-CD4 and TC-CD8 (Caltag) in
PBS–2% fetal bovine serum, washed, and resuspended in PBS–1% formaldehyde
as previously described (22, 39).
U-373-MAGI assays. MAGI assays were performed as previously described
using U-373-MAGI-CCR5E and U-373-MAGI-CXCR4CEM glioblastoma cells
(42). Briefly, 24 h prior to infection, each of the MAGI cell lines were seeded into
48-well culture plates (2 3 104 cells/well). Virus stocks amplified in PHA-
activated PBMCs as described below were diluted to approximately 104 IU/ml,
and 100 ml was used to infect duplicate wells of each of the three cell lines for 2 h
at 37°C. At 48 h postinfection (hpi) the cells were stained, and the number of
blue foci in each well was counted. To analyze the sensitivity of HXB2 or
HXB2/LW to AMD3100 (11; kindly provided by J. Moore, Cornell Medical
School, New York, N.Y.), medium containing 0.15 to 15 ng of AMD3100/ml was
added to the virus stock prior to infecting the U-373-MAGI-CXCR4CEM cells.
AMD3100 inhibition of CXCR4 entry in PBMCs and HF-TOC. AMD3100 was
added to the virus supernatant at a concentration of 100 ng/ml prior to infection
of the PHA-activated PBMCs, to inhibit CXCR4-mediated viral entry (11, 25).
Virus replication was detected by RT assays of culture medium aliquots removed
every 3 days. To inhibit CXCR4-mediated virus entry in HF-TOC assays,
AMD3100 (100 ng/ml) was added to fresh HF-TOC medium every day. Thymo-
cytes were analyzed for viral replication by p24 ELISA as described above.
Fusogenicity assay. pcENV-NL4 is a pcDNA3-based vector containing the
EcoRI-XhoI fragment of the NL4-3 env gene (H. Zhang and L. Su, unpublished
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data). The EcoRI-XhoI fragment of HXB2/LW or HXB2 was cloned into
pcDNA3 to produce pcENV-LW or pcENV-HXB2 plasmid constructs. 293T
cells were cotransfected with a plasmid expressing the HIV-1 Tat gene and the
env expression vector using Effectene Transfection reagent (Qiagen). At 24 h
posttransfection (hpt), the Jurkat cells stably transfected with the HIV-1 long
terminal repeat (LTR) luciferase gene (1G5, provided by the NIH AIDS Re-
search and Reference Reagent Program) were cocultured with the transfected
293T cells. Tat-induced luciferase expression in 1G5 cells was measured at 24 h
postcoculture (48 hpt).
Heat-stability analysis of HIV-1 stocks. Equal numbers of HXB2 or
HXB2/LW infectious units, as determined on MAGI cells, were incubated at the
indicated temperatures for 10 min, and the remaining infectious units were
determined on U-373-MAGI-CXCR4 indicator cells as described above. Tripli-
cate samples were included in each experiment.
Western blot analysis. Transfected 293T cells were lysed 48 hpt in 0.5% NP-40
lysis buffer as described elsewhere (22). To detect viral proteins in virions,
supernatants containing viruses were centrifuged for 2 h at 4°C in a standard 20%
sucrose cushion as described previously (1). Virus pellets were lysed in 1% Triton
X-100 and analyzed by standard Western blotting with HIV-positive patient sera
(provided by the NIH AIDS Research and Reference Reagent Program).
RESULTS
T-cell-line-attenuated HIV-1 isolates acquired activity in
vivo to infect macrophages and to replicate in the human
thymus models. Four highly related HIV-1 clones derived from
Lai/IIIB were used to investigate the viral envelope gp120
determinants associated with replication in macrophages and
in the in vivo human thymus models (Fig. 1A). HXB2 is an
infectious HIV-1 molecular clone of Lai/IIIB with mutations
that lead to premature termination in the ORFs of three ac-
cessory proteins, Vpr, Vpu, and Nef. Like Lai/IIIB, HXB2
replicates efficiently in T-cell lines in vitro but lacks the ability
to replicate in vivo (8, 40). The other three clones contain
HIV-1 sequences from the laboratory worker who was acci-
dentally infected with Lai/IIIB. Previous reports show that a
recombinant virus that contains the env gene from LW in an
HXB2 background, HXB2/LW, in contrast to Lai/IIIB or
HXB2, replicates efficiently in human thymus models. The V3
loop regions between these two viruses differ in six amino
acids, including the alanine (A)-to-threonine (T) change at the
tip of the V3 loop (36, 40). The A-to-T change is known to be
responsible for escape from certain neutralizing monoclonal
antibodies specific to the HXB2 (IIIB) envelope. In this study
we also used two additional viruses, LW/C and LW/C IIIB, that
are derived from LW and are macrophage tropic (28). LW/C is
a viral clone that was derived from virus isolated from the
infected laboratory worker, with repaired vif, vpr, and nef
ORFs. LW/CIIIB is identical to LW/C except for the T-to-A
(back to IIIB) change in the V3 loop region.
As expected, both LW/C and HXB2/LW efficiently infected
MDM. LW/CIIIB, with the T-to-A back mutation, also repli-
cated in MDM, and HXB2 failed to replicate in MDM (Fig.
1B). Therefore, the A-to-T mutation selected early in vivo in
the laboratory worker was not required for the acquired rep-
lication activity of LW/C in macrophages. It may contribute to
other important activities for in vivo replication.
A single amino acid change in the V3 loop region, but not
MDM tropism, contributed to HIV-1 replication in the human
thymus. Replication of HXB2 and the LW viruses was ana-
lyzed in the HF-TOC and SCID-hu Thy/Liv mouse model
systems. In HF-TOC, HXB2 exhibited no significant replica-
tion, whereas HXB2/LW infection resulted in 1,000-fold-
higher levels of viral replication, similar to those of NL4-3 and
JR-CSF (Fig. 2A). This is consistent with our previous report
(40). LW/C, a macrophage-tropic LW clone, was also observed
to replicate to high levels in HF-TOC, approximately 100-fold
higher than that for HXB2. In contrast, LW/CIIIB, which dif-
fers by one amino acid from LW/C (Fig. 1A), exhibited no
FIG. 1. Replication of LW clones in MDM. (A) Genomic organization of HXB2 and LW-derived HIV-1 clones. In panel a, the HXB2 HIV-1
genome has nonsense mutations within the vpr, vpu, and nef ORFs, denoted by asterisks. A six-amino-acid sequence within the V3 loop is
highlighted (white segment). In panel b, HXB2/LW was created by replacing the SalI-BamHI fragment from LW12.3 (striped segment) into an
HXB2 background. The V3 loop is in white, with the amino acid change to Thr (T) in bold. In panel c, LW/C is a full-length macrophage-tropic
clone derived from the LW isolate LW12.3. LW/C contains repaired vif, vpr, and nef accessory ORFs (28). In panel d, LW/C IIIB is identical to
LW/C except for the T-to-A (back to HXB2) change at the V3 loop. (B) Replication of the LW clones in MDM. Monocytes were cultured and
infected with each HIV-1 stock. HIV-1 replication was monitored by measuring virion-associated RT activity (3H activity, in counts per minute per
milliliter) in the culture medium. Experiments were repeated with independent PBMC donors with similar results.
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significant replication in the thymus. The SCID-hu Thy/Liv
mouse model was also used to confirm that HXB2 showed no
significant replication, whereas HXB2/LW replicated to high
levels (40). For LW/C, replication was also readily detectable,
whereas LW/CIIIB replication was undetectable (Fig. 2B and
data not shown). Therefore, the replication of each virus in the
Thy/Liv organ is similar to that in the HF-TOC model. Fluo-
rescence-activated cell sorter analyses of T cells from thymus
organs infected with HXB2/LW and LW/C, but not HXB2 and
LW/CIIIB, showed upregulation of major histocompatibility
complex class I in the CD41CD81 double-positive thymocytes
from both the HF-TOC and SCID-hu Thy/Liv mice (data not
shown). This is consistent with previous findings that showed
that productive HIV-1 infection in the thymus induces upregu-
lation of major histocompatibility complex class I antigens
upon infection (22). These data suggest that the A-to-T con-
version in the V3 loop of LW/C contributes to the acquired
replication in the thymus in vivo but not to its replication in
MDM (Fig. 1B).
The in vivo-selected HIV-1 clones still used CXCR4 as co-
receptor for entry. To address the observation of differential
cell tropism of the highly related viruses, we first looked at
coreceptor usage by each virus. We hypothesized that the abil-
ity to replicate in MDM and in the thymus could be due to a
change from using the CXCR4 (IIIB) coreceptor to the CCR5
coreceptor (5). To test this hypothesis, we analyzed each virus
on MAGI cells expressing CD4 and either the CCR5 or
CXCR4 coreceptor (42). All three LW viruses, as well as
HXB2, used the CXCR4 (not CCR5) coreceptor for entry
(Fig. 3A). This indicated that the change in tropism was not
due to a change in coreceptor preference. As a positive control
for CCR5 entry in this system, we used the CCR5-tropic
JRCSF virus to infect the CCR5-expressing MAGI cells.
JRCSF efficiently utilized the CCR5 coreceptor and not the
CXCR4 coreceptor for entry (Fig. 3A).
In order to determine if CXCR4 was the only coreceptor
used in vivo and in primary PBMCs, we used a specific inhib-
itor of CXCR4-tropic HIV-1, the bicyclam AMD3100, to spe-
cifically block virus entry via this coreceptor (11, 25). We an-
alyzed the effect of AMD3100 on viral replication in both
PBMCs and HF-TOC. NL4-3, HXB2, and HXB2/LW were all
efficiently inhibited by AMD3100 in PBMCs, whereas JRCSF
was not (Fig. 3B). In the HF-TOC assay, NL4-3 was used as a
positive CXCR4 control due to the lack of HXB2 replication in
the thymus. AMD3100 was able to efficiently inhibit both
NL4-3 and HXB2/LW replication but not replication of the
CCR5-utilizing virus JRCSF (Fig. 3C). Since CXCR4 is the
only HIV-1 entry coreceptor that is sensitive to AMD3100, this
result indicated that HXB2/LW used predominantly CXCR4
as coreceptor in the thymus. In addition, we showed that the
HXB2/LW env protein used CXCR4, but not CCR5, corecep-
tor to fuse with MDM and macrophage cell lines, and its fusion
with MDM was efficiently inhibited by AMD3100 (Fig. 3D).
Further supporting the notion that LW uses CXCR4 and not
CCR5 for entry into macrophages, there was no difference in
the overall level of fusion, compared with wild-type macro-
phages, when CCR5-negative macrophages obtained from a
donor homozygous for the D32 deletion allele were used as
targets (data not shown). These data suggest that, like Lai/IIIB
and HXB2, the LW virus also predominantly used CXCR4 as
coreceptor for entry in the thymus, macrophages, and PBMCs.
LW and HXB2 Env proteins showed similar affinity for
CXCR4 and fusogenicity. To further investigate the different
replication activity exhibited by HXB2/LW and HXB2 in the
thymus in vivo, we analyzed the efficiency of these two viral
envelopes to utilize CXCR4 in competing concentrations of
AMD3100. Virus (HXB2 or HXB2/LW) was incubated with
various concentrations of AMD3100 and allowed to infect
MAGI-CXCR4 cells. The induction of b-galactosidase activity
by HIV-1 infection was quantitated as a measure of fusion and
viral entry. As shown in Fig. 4A, the dose of AMD3100 re-
quired to inhibit HXB2 and HXB2/LW was the same. These
data suggest that the HXB2 and LW Env proteins had a similar
affinity for CXCR4 and interacted similarly with CXCR4 for
entry.
To test if the LW Env protein had increased fusion activity,
we performed the fusogenicity assay by coculturing a Jurkat
T-cell line stably expressing the luciferase reporter gene under
control of the HIV-1 LTR with 293T cells transfected with
FIG. 2. Replication of LW clones in the human thymus. (A) Rep-
lication of LW clones in HF-TOC. Shown is the level of p24 present in
HF-TOC at 10 to 12 days postinfection (dpi), with HXB2, HXB2/LW,
LW/C, LW/CIIIB, NL4-3, and JRCSF. Error bars are standard devi-
ations based on three or more independent experiments. (B) Replica-
tion of LW clones in SCID-hu Thy/Liv mice. Shown is the level of p24
present in the SCID-hu Thy-Liv organ at 4 and 6 weeks postinfection
(wpi) with HXB2, HXB2/LW, LW/C, LW/CIIIB, and NL4-3. Error
bars represent standard deviations.
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HIV-1 Tat and the env gene from HXB2, NL4-3, or HXB2/LW
(Fig. 4B). The three HIV-1 Env proteins mediated similar
levels of fusion with the Jurkat T cells, as indicated by the
enhanced luciferase activity mediated by HIV-1 Tat. There-
fore, the LW Env protein showed no increased fusogenicity
over the HXB2 Env.
HXB2/LW produced more infectious virions with increased
levels of glycoproteins. To analyze the quality of the LW viri-
ons, HIV-1 viral supernatants of HXB2 or HXB2/LW were
analyzed by RT (total virions) and infectious unit (infectious
virions) assays. Infection of PHA-activated PBMCs with HXB2
and HXB2/LW yielded comparable RT activity (total virions)
FIG. 3. HXB2/LW, LW/C, and LW/CIIIB utilize the same coreceptor (CXCR4) as HXB2. (A) The LW viruses used CXCR4 but not CCR5
as coreceptor for entry. HIV-1 viral supernatants were used to infect the CXCR4- or CCR5-MAGI cells. Each virus was scored for the number
of blue cells per milliliter for both cell lines. HXB2, HXB2/LW, LW/C, and LW/CIIIB utilized CXCR4 (gray) as the primary coreceptor. JRCSF,
a macrophage-tropic virus, utilized CCR5 (black) for entry. (B) HXB2/LW only utilized CXCR4 for entry into PBMCs. The bicyclam AMD3100,
a specific inhibitor of HIV-1 using the CXCR4 coreceptor, was added (15 ng/ml) to the media for the PBMC culture. Shown is AMD3100 inhibition
in PBMC cultures at 9 dpi. HIV-1 replication for each virus in the absence of AMD3100 is normalized to 100% (wild-type; black bar). Error bars
represent standard deviations. Three independent experiments were performed with similar results. JRCSF was used as a CCR5-tropic HIV-1
resistant to AMD3100 inhibition. (C) HXB2/LW only used CXCR4 as a coreceptor for infection in the human thymus. Shown is the relative
replication (based on picograms of p24 per 106 T cells) of each virus with AMD3100 in HF-TOC. HIV-1 replication for each virus in the absence
of AMD3100 is normalized to 100% (wild-type; black bar). Relative replication of NL4-3 (checked bar), HXB2/LW (gray bar), and JRCSF (striped
bar) in the presence of AMD3100 is presented. Error bars represent standard deviations. Three independent experiments were performed with
similar results. JRCSF was used as a CCR5-tropic HIV-1 resistant to AMD3100 inhibition. (D) HXB2/LW Env used only CXCR4 as a coreceptor
for infecting macrophages. env genes from HX/LW or the CXCR4-dependent macrophage-tropic strain UG024 were expressed in 293T cells and
tested for the ability to mediate fusion with primary human MDM or with U87 cells expressing CD4 alone or CD4 in conjunction with CCR5 or
CXCR4. Macrophages were pretreated for 1 h with or without the CXCR4 antagonist AMD3100 (10 mg/ml). Data are expressed as the percentage
of fusion relative to untreated MDM or relative to U87/CD4/CXCR4 cells. Error bars are the standard deviations of three independent
experiments.
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in culture supernatants, suggesting that the LW Env did not
affect expression, assembly, and release of total viral particles
(data not shown). However, HXB2 viral stocks contained only
about 10 to 15% of the infectious units of HXB2/LW viral
stocks with the same amount of total virions (P , 0.01), indi-
cating that HXB2/LW produced more infectious viral particles
than HXB2 (Fig. 5A). These data indicate that the HXB2/LW
virus enhanced assembly or stability of infectious virions.
To examine viral proteins in the virions, pelleted HXB2 or
HXB2/LW virions were analyzed by Western blotting using
human anti-HIV serum. The relative level of gp41, gp120, or
p24 was measured by densitometry (Fig. 5B and Table 1).
Relative to p24 levels, HXB2/LW virions contained approxi-
mately threefold more gp120 than HXB2 virions, although the
gp41 levels relative to p24 were not significantly different (Ta-
ble 1). Comparable levels of cell-associated gp41 and gp120
(relative to levels of p24/p25) were synthesized in transfected
or infected cells (data not shown), indicating that HXB2/LW
did not significantly affect the synthesis and proteolytic cleav-
age of the Env precursor. Interestingly, the single A-to-T mu-
tation in LW/C contributed to the increased virion association
of gp120, because LW/C showed a similar increase of gp120 in
the virions in comparison to LW/CIIIB, which differs by one
amino acid (T to A) at the V3 loop (Fig. 5 and Table 1). These
results collectively suggest that the LW Env protein acquired
mutations that lead to enhanced gp120 association with virions,
probably through stabilization of the gp120-gp41 interaction.
DISCUSSION
From a laboratory worker accidentally exposed to a T-cell-
line-adapted HIV-1 isolate, Lai/IIIB, viruses have been recov-
ered that have reverted to replicating in macrophages and in
the human thymus in vivo (40, 44). Utilizing the SCID-hu
Thy/Liv mouse and HF-TOC as in vivo models for HIV-1
replication, we demonstrated that HIV-1 selected in the labo-
ratory worker acquired activity for replication in vivo and for
replication in the macrophages. In addition, the macrophage
tropism was genetically separable from the replication activity
in the human thymus. A single mutation in the V3 loop of the
LW Env protein impaired the replication activity of the LW/C
clone in the human thymus without affecting its replication
activity in macrophages. We demonstrated that HIV-1 selected
in the laboratory worker acquired altered tropism without a
change in coreceptor usage. We further demonstrated that the
LW virus produced more infectious virions than the LAI/IIIB
clone HXB2, and more HIV-1 gp120 was associated with LW
virions than HXB2 virions.
The HF-TOC and the SCID-hu Thy/Liv mouse have served
as useful models for the analysis of normal thymocyte differ-
entiation (23, 24, 31, 41, 43) and HIV-1 pathogenesis in vivo (8,
22, 40). As judged by the parameters of viral replication, tro-
pism, cytopathic effects, and in vivo antiviral effects, these
models both appear to faithfully reproduce the expected at-
tributes of HIV-1 infection in vivo (2, 3, 7, 17, 18, 32, 38, 39).
For example, multiple cell types are maintained in both thymus
models, and thymocyte subsets are present at normal propor-
tions, with quiescence phenotypes similar to the human thymus
in vivo. Most importantly, laboratory-attenuated HIV-1 iso-
lates like LAI/IIIB and HXB2 fail to replicate in the SCID-hu
Thy/Liv mouse or in HF-TOC (8, 22, 40). HIV-1 determinants
specifically involved in replication and pathogenesis in vivo
have been defined using both thymus models (12, 40). There-
fore, both SCID-hu Thy/Liv mice and HF-TOC are relevant
models of HIV-1 replication in the thymus in vivo.
Thymocytes are clearly the primary cells infected by
HXB2/LW in HF-TOC or SCID-hu Thy/Liv mice. First, HIV-1
replication was detected in thymocytes by both thymocyte-
associated p24 assay and immunohistochemistry (Fig. 2 and
reference 12). Second, monocytes or macrophages comprise a
FIG. 4. HXB2/LW Env shows normal affinity for CXCR4 corecep-
tor and fusion activity. (A) Serial dilutions of AMD3100 were used to
determine the inhibitory dose for HXB2 (black line) and HXB2/LW
(dashed line) to infect CXCR4-MAGI cells. Results are indicated as
the percentage of replication compared to replication in the absence of
AMD3100. Error bars represent standard deviations. (B) The HXB2
env and LW env showed similar fusogenic activity. The IG5 Jurkat cell
line with the LTR-luciferase gene was cocultured with 293T cells
transfected with HIV-1 Tat and one of the HIV-1 env genes (HXB2,
HXB2/LW, or NL4-3). Tat-mediated LTR activation after fusion was
measured by luciferase activity (in relative light units [RLU]). Three
independent experiments were performed with similar results.
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minute cell population in the thymus (31, 33). Third, a point
mutation that did not affect the replication of LW/C in MDM
significantly impaired its replication in HF-TOC or SCID-hu
Thy/Liv mice (Fig. 2). Fourth, the same coreceptor (CXCR4)
that is expressed by most thymocytes is predominantly used by
both HXB2 and the LW virus (Fig. 3).
Cytokines that can enhance HIV-1 replication have been
shown to be upregulated in human thymus organs productively
infected with HIV-1 (reference 22 and unpublished observa-
tions). One likely mechanism of enhanced replication by the
LW virus is that HXB2/LW or LW/C infected certain target
cells (thymocytes or macrophages) to sensitize or enhance the
ability of thymocytes to support HIV-1 replication. Identifica-
tion of those “initiator cells” will be of importance in under-
standing the enhanced replication of HXB2/LW. Alternatively,
the increased LW env gp120 in the LW virions may enhance
the infectivity or transmission of HXB2/LW to infect human
thymocytes. The low level of replication of HXB2 in the Thy/
Liv organ at late times postinfection (Fig. 2 and reference 40)
suggests that HXB2 can infect target cells in the Thy/Liv organ.
However, it either replicates or transmits very slowly in the
target cells, probably due to reduced levels of gp120 in the
HXB2 virions. It is also possible that HXB2 at late times may
have acquired mutations that contribute to enhanced replica-
tion. It will be of interest to analyze the HXB2 genome from
late times postinfection for possible accumulation of specific
mutations (e.g., in nef and/or env V3 loop regions).
In other lentiviruses, single point mutations in nef have been
shown to convert an attenuated virus to a pathogenic one with
an enhanced replication activity in vivo (20). The present study
documents the in vivo selection of a unique structural deter-
minant in HIV-1 that appears to be necessary for infectivity in
the thymus organ in vivo, but not in MDM, PBMCs, or in
immortalized T-cell lines in vitro. The relevant change does
not affect the nef gene, previously implicated for infectivity of
simian immunodeficiency virus in rhesus macaques (20), or of
HIV-1 in SCID-hu mice (17). Thus, novel features of the V3
region of env that are necessary for infection of natural target
cells in vivo are revealed by analyses of HIV-1 isolates in the
human thymus organ models. In a separate study, we showed
that HXB2/LW replicated efficiently in the thymus models with
no significant pathogenicity or thymocyte depletion (12).
Therefore, other mutations specifically defective for pathoge-
nicity in the LW genome are implicated.
It has been reported that env mutations in an in vivo-pas-
saged SHIV are associated with increased resistance to neu-
FIG. 5. HXB2/LW produced more infectious virions with higher levels of Env gp120. (A) The HXB2/LW viral stock contained higher fractions
of infectious virions. The infectious virions and total virions from HXB2 or HXB2/LW viral stocks prepared from PBMCs were measured. The
relative infectious virions (IU/RT) are presented. Standard deviations are shown as error bars. Three independent experiments were analyzed with
similar results. (B) The HXB2/LW and LW/C virions contained higher levels of gp120. Pelleted virions were analyzed by Western blotting with
HIV-positive human patient sera. The gp120, gp41, and major gag proteins are indicated. The level of gp120 or gp41for each virus relative to p24
capsid protein was calculated (gp120/p24 or gp41/p24; Table 1).
TABLE 1. Summary of HIV gp120/p24 and gp41/p24 ratios relative
to those for HXB2
Expt no. Proteinsa
Protein ratio
HXB2b HXB2/LW LW/C LW/CIIIB
1 gp120 and p24 1.0 2.0 NDc ND
gp41 and p24 1.0 1.0 ND ND
2 gp120 and p24 1.0 3.3 ND ND
gp41 and p24 1.0 1.3 ND ND
3 gp120 and p24 1.0 2.8 6.4 1.4
gp41 and p24 1.0 1.2 1.3 1.4
a The level of each protein was calculated by densitometer (see Fig. 5B).
b Ratios of HXB2 gp120/p24 and gp41/p24 were set at 1.0.
c ND, not done.
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tralizing antibodies (13). With viruses isolated 4 years after the
isolation of LW/C from the infected laboratory worker, a re-
cent report suggests that env mutations in the in vivo revertants
are involved in increased resistance to neutralizing antibodies
and in AIDS development (4). Interestingly, the A-to-T mu-
tation in the env V3 loop common to LW/C, HXB2/LW (40),
and other isolates from the infected laboratory worker (27, 44)
is also associated with escape from antibody neutralization
(10). Neutralizing antibodies are probably not involved in the
SCID-hu Thy/Liv mouse or HF-TOC models. Therefore, the
loss of replication of LW/CIIIB in the thymus models suggests
that the A-to-T mutation selected in vivo may play an impor-
tant role in the reversion of infectivity in vivo, independent of
its possible escape from antibody neutralization. Further anal-
yses of these recombinant viruses in different cells such as
MDM and PBMCs in vitro and in the thymus models in vivo
will shed light on our understanding of HIV-1 attenuation in
vitro and reversion in vivo.
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